Investor Profile: Claris Capital — Thesis, Cheque Size & How to Apply

If you are building in consumer, healthtech or sustainability, here is how to get funding from Claris Capital. The Ahmedabad-based venture arm of the Claris group — founded by Krishna Handa — invests off the legacy of Claris Lifesciences, the pharma company the group built and sold to Baxter for $625 million in 2017. Claris Capital funding follows the founder's stated interest in innovation and sustainable impact.

Thesis and sweet spot

Claris Capital seeks out innovative startups across consumer/D2C, healthtech, clean energy, agri-bio and aerospace. It is a thesis-driven, concentrated investor rather than a spray-and-pray seed fund, typically entering at seed and Series A with occasional later-stage participation. The Claris group's own story shapes the lens: Claris Lifesciences was built from Ahmedabad into a global sterile-injectables business and sold to Baxter — so the firm understands regulated industries, manufacturing depth and the long build. Founders in healthtech and clean energy get investors who have lived through FDA-grade execution, while consumer founders get a group with decades of brand and distribution experience.

Cheque size and fund

The firm has not publicly disclosed its fund size or standard cheque range — treat it as not publicly disclosed. Its pace is deliberate, averaging about one new investment a year over the past decade.

Notable portfolio

Reported investments include Bold Care (men's health, Series A in December 2024), Loopworm (insect biotech, seed in July 2025), Prescinto (energy analytics, acquired by IBM in October 2024), Woodsmen Mountain Whiskey, Garuda Aerospace (drones) and KiviHealth (healthtech).

The portfolio's spread — from insect protein to men's health to mountain whiskey — reflects the firm's willingness to back strong founders in unglamorous categories, not just hot sectors. Its one exit to date, Prescinto's acquisition by IBM, validates the clean-energy technology bet.

Partners

The investment team includes founder Krishna Handa, Partner Ajay Jadeja, Principal Jignesh Panchal and Principal Nikhil Jain, operating from Ahmedabad.

Programs, credits and perks

Claris Capital runs no public accelerator; founders get the backing of an operator family that has built and exited a large pharma business in India.

How to apply for funding

The firm publishes no application form. Reach out through the contact details on the official website at clariscapital.in (the firm lists its Ahmedabad office). A warm introduction through the pharma and healthcare network around the Claris group carries weight.